Trial Profile
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of RO5095932 Administered Once Weekly for 4 Weeks in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs RO 5095932 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 12 Dec 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 15 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 23 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche.